Literature DB >> 32060147

Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.

Koen Schipper1, Anne Paulien Drenth1, Eline van der Burg1, Samuel Cornelissen1, Sjoerd Klarenbeek2, Micha Nethe3, Jos Jonkers3.   

Abstract

Invasive lobular carcinoma (ILC) accounts for 8%-14% of all breast cancer cases. The main hallmark of ILCs is the functional loss of the cell-cell adhesion protein E-cadherin. Nonetheless, loss of E-cadherin alone does not predispose mice to mammary tumor development, indicating that additional perturbations are required for ILC formation. Previously, we identified an N-terminal truncation variant of ASPP2 (t-ASPP2) as a driver of ILC in mice with mammary-specific loss of E-cadherin. Here we showed that expression of t-ASPP2 induced actomyosin relaxation, enabling adhesion and survival of E-cadherin-deficient murine mammary epithelial cells on stiff matrices like fibrillar collagen. The induction of actomyosin relaxation by t-ASPP2 was dependent on its interaction with protein phosphatase 1, but not on t-ASPP2-induced YAP activation. Truncated ASPP2 collaborated with both E-cadherin loss and PI3K pathway activation via PTEN loss in ILC development. t-ASPP2-induced actomyosin relaxation was required for ILC initiation, but not progression. Conversely, YAP activation induced by t-ASPP2 contributed to tumor growth and progression while being dispensable for tumor initiation. Together, these findings highlight two distinct mechanisms through which t-ASPP2 promotes ILC initiation and progression. SIGNIFICANCE: Truncated ASPP2 cooperates with E-cadherin and PTEN loss to drive breast cancer initiation and progression via two distinct mechanisms. ASPP2-induced actomyosin relaxation drives tumor initiation, while ASPP2-mediated YAP activation enhances tumor progression. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32060147      PMCID: PMC7611216          DOI: 10.1158/0008-5472.CAN-19-3607

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains.

Authors:  X Espanel; M Sudol
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

2.  Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.

Authors:  Takaaki Fujii; Reina Yajima; Sasagu Kurozumi; Toru Higuchi; Sayaka Obayashi; Hideaki Tokiniwa; Rin Nagaoka; Daisuke Takata; Jun Horiguchi; Hiroyuki Kuwano
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

3.  Invasive lobular carcinoma of the breast: incidence and variants.

Authors:  V Martinez; J G Azzopardi
Journal:  Histopathology       Date:  1979-11       Impact factor: 5.087

4.  Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

Authors:  Patrick W B Derksen; Xiaoling Liu; Francis Saridin; Hanneke van der Gulden; John Zevenhoven; Bastiaan Evers; Judy R van Beijnum; Arjan W Griffioen; Jacqueline Vink; Paul Krimpenfort; Johannes L Peterse; Robert D Cardiff; Anton Berns; Jos Jonkers
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

Review 5.  Myosin phosphatase target subunit: Many roles in cell function.

Authors:  Fumio Matsumura; David J Hartshorne
Journal:  Biochem Biophys Res Commun       Date:  2007-12-26       Impact factor: 3.575

6.  The structure and interactions of the proline-rich domain of ASPP2.

Authors:  Shahar Rotem; Chen Katz; Hadar Benyamini; Mario Lebendiker; Dmitry Veprintsev; Stefan Rüdiger; Tsafi Danieli; Assaf Friedler
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

7.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Cynthia C Bartholomae; Marco Ranzani; Fabrizio Benedicenti; Lucia Sergi Sergi; Alessandro Ambrosi; Maurilio Ponzoni; Claudio Doglioni; Clelia Di Serio; Christof von Kalle; Luigi Naldini
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

Review 8.  ASPP: a new family of oncogenes and tumour suppressor genes.

Authors:  A Sullivan; X Lu
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

9.  E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

Authors:  C B Vos; A M Cleton-Jansen; G Berx; W J de Leeuw; N T ter Haar; F van Roy; C J Cornelisse; J L Peterse; M J van de Vijver
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.

Authors:  Grazia Arpino; Valerie J Bardou; Gary M Clark; Richard M Elledge
Journal:  Breast Cancer Res       Date:  2004-02-17       Impact factor: 6.466

View more
  2 in total

Review 1.  Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.

Authors:  Amy E McCart Reed; Lauren Kalinowski; Peter T Simpson; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2021-01-07       Impact factor: 6.466

Review 2.  Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

Authors:  George Sflomos; Koen Schipper; Thijs Koorman; Amanda Fitzpatrick; Steffi Oesterreich; Adrian V Lee; Jos Jonkers; Valerie G Brunton; Matthias Christgen; Clare Isacke; Patrick W B Derksen; Cathrin Brisken
Journal:  Cancers (Basel)       Date:  2021-10-27       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.